EGFR and metastatic colorectal cancer: Following the analysis of these biomarkers, a retrospective study involving 102 patients with metastatic colorectal cancer (mCRC) treated with anti-EGFR monoclonal antibodies combined with first-line chemotherapy examined the relationship between baseline levels of TPS, CEA, and CA 19-9 and clinical outcomes, such as progression-free survival.